The 20 Best Spinal Muscular Atrophy Type 3 Doctors in Maryland, US

Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).

Dr. Tom Crawford has been a member of the Department of Neurology since 1987. He is co-director of the MDA clinic for Neuromuscular Disorders and Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins. His practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders. Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia. He is also actively involved in the Biology of neurofilaments by characterization of transgenic animal models. He is on the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy, and the Medical Advisory Committee for the Muscular Dystrophy Association. He is the Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins, which has evaluated almost half of the known patients with this disorder in the United States. Additional specific clinical interests include evaluation and treatment of children with brachial plexus palsies. Dr. Crawford received his medical degree from the University of Southern California. He completed a pediatric internship and residency at the Pediatric Pavilion of the Los Angeles County / University of Southern California Medical Center, followed by a pediatric chief residency. He completed his training in Neurology with Special Qualification in Child Neurology at the Los Angeles Childrens Hospital. He then traveled east to the laboratory of Dr John Griffin at Johns Hopkins for a fellowship in Neuromuscular Disorders. Prior to medical training and Neurology residency, he majored in Psychology and Religion at Yale College. Dr. Crawford has published extensively and presented nationally and internationally. He has an active role in teaching medical students and residents in neurology. In addition, Dr. Crawford has special interest and experience in EMG studies of children and adults. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Ataxia-Telangiectasia, and Spinal Muscular Atrophy Type 2.

Dr. Jeffrey Rothstein focuses on neuromuscular diseases, with a particular focus on Amyotrophic lateral sclerosis (ALS). Other clinical areas relevant to his laboratory-based research include idiopathic stupor, epilepsy, and motor neuron degeneration. His laboratory includes more than 25 post-doctoral fellows, neurology residents, neuromuscular fellows, junior faculty, undergraduate students, technicians, and ALS clinic staff. He has been the principal and/or local investigator in more than 20 national or international trials in ALS. He is the author of more than 360 articles on basic and clinical neuroscience. Dr. Rothstein's laboratory research is funded through the National Institutes of Health, the Dept of Defense, Target ALS, Maryland TEDCO, Alzheimer's Drug Discovery Foundation, the Muscular Dystrophy Association, the ALS Association, and Answer ALS. Dr. Jeffrey Rothstein received a masters degree in neurochemistry from the University of Chicago and a Ph.D. in physiology and biophysics from the University of Illinois Health Sciences Center. He then obtained his medical degree from the University of Illinois College of Medicine. He went on to complete an internship at the University of North Carolina Memorial Hospital before joining The Johns Hopkins for his residency. While at Johns Hopkins, he became chief resident in neurology and completed his fellowship in neuromuscular disease. He has been Professor of Neurology and Neuroscience at Johns Hopkins for more than 25 years. Dr. Rothstein is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Spinal Muscular Atrophy Type 3.

Vinay Chaudhry is a Neurologist in Baltimore, Maryland. Dr. Chaudhry is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myasthenia Gravis, Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Advanced Bronchoscopy.

Chandana Chauhan is a Neurologist in Baltimore, Maryland. Dr. Chauhan is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy (SMA), and Spinal Muscular Atrophy Type 3.

Dr. Brett Morrison specializes in neuromuscular disorders in adults including peripheral neuropathies, amyotrophic lateral sclerosis, myasthenia gravis and muscle diseases. Dr. Morrison is currently the site principal investigator for clinical trials investigating new treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) and painful diabetic peripheral neuropathy. Dr. Morrison's research interests include investigations into the mechanisms of nerve regeneration and common peripheral neuropathies. Current research focuses on better understanding the role of the immune system in peripheral nerves and targeting these pathways for the development of new treatments. Dr. Brett Morrison received his M.D. and Ph.D. from Mount Sinai Medical School in New York City. He completed his medical internship at the University of Maryland and residency in neurology at The Johns Hopkins Hospital. He then completed a fellowship in Clinical Neurophysiology at The Johns Hopkins Hospital. Dr. Morrison is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy (SMA).

Dr. Charlotte Sumner is a Professor of Neurology and Neuroscience at Johns Hopkins University School of Medicine. Dr. Sumner cares for patients with genetically-mediated neuromuscular diseases. Her practice is notable for a focus on individuals with inherited neuromuscular disorders of peripheral nerves and motor neurons, including spinal muscular atrophy (SMA) and Charcot-Marie-Tooth (CMT) disease. She co-directs the Johns Hopkins Muscular Dystrophy Association Care Center, the Spinal Muscular Atrophy (SMA), and the Charcot-Marie-Tooth (CMT) clinics, which deliver multidisciplinary clinical care, engage in international natural history studies, and provide cutting edge therapeutics. Dr. Sumner’s research focuses on developing treatments for degenerative disorders of motor neurons and peripheral nerves. Her laboratory uses human tissues and induced pluripotent cell lines, mouse models and cultured cells to characterize disease mechanisms and develop treatments. Dr. Charlotte Sumner received her medical degree from the University of Pennsylvania School of Medicine following undergraduate studies at Princeton University. She completed internal medicine internship and neurology residency at the University of California San Francisco, after which she returned to the east coast for a neuromuscular fellowship at Johns Hopkins and a neurogenetics fellowship in the Neurogenetics Branch at the National Institute of Neurological Disorders and Stroke. She joined the neurology faculty at Johns Hopkins in 2006. Dr. Sumner is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth Disease, Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, and Gastrostomy.

James Russell is a Neurologist in Baltimore, Maryland. Dr. Russell is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Cramp-Fasciculation Syndrome, Peripheral Neuropathy, and Thyroidectomy.

Peter Jin is a Neurologist in Baltimore, Maryland. Dr. Jin is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), and Gastrostomy.

Neil Porter is a Neurologist in Baltimore, Maryland. Dr. Porter is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Myasthenia Gravis, Mononeuritis Multiplex, Multiple Mononeuropathy, Riboflavin Transporter Deficiency Neuronopathy, and Gastrostomy.

Dr. Ahmet Hoke is Professor of Neurology and Neuroscience, W. W. Smith Charitable Trust Professor of Neuroimmunology at Johns Hopkins School of Medicine, Director of the Daniel B. Drachman Division of Neuromuscular Diseases and Director of the Merkin Peripheral Neuropathy and Nerve Regeneration Center at Johns Hopkins University School of Medicine. He completed his medical training at Hacettepe University School of Medicine in Ankara, Turkey followed by his PhD studies in developmental neuroscience at Case Western Reserve University in Cleveland, Ohio, and neurology residency at Johns Hopkins Hospital. After completing his neuromuscular training at University of Calgary, Canada, he returned to Johns Hopkins University as faculty and rose through the ranks. He is the recipient of several awards including Derek Denny Brown Young Neurological Scholar Award (2005) and Wolfe Neuropathy Research prize (2018) given by the American Neurological Association, Myung Memorial Lecture Award (2017) by the Korean Neurological Association, Nejat Eczacibasi Medical Scientist Award (2019) by the Eczacibasi Foundation, Turkey, and Alan J. Gebhart Prize in Excellence in Neuropathy Research (2022) by the Peripheral Nerve Society. He is an Ex-Officio member of the Board of Directors of the American Neurological Association, and Vice-President of the Toxic Neuropathy Consortium. He serves on several editorial boards and is the Editor-in-Chief of Annals of Clinical and Translational Neurology. Dr. Hoke is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Wallerian Degeneration, Peripheral Neuropathy, Tomaculous Neuropathy, Spinal Muscular Atrophy with Arthrogryposis, and Prostatectomy.

Dr. Pardo's interest in transverse myelitis centers on management of acute myelitis, biomarkers of the disease in cerebrospinal fluid (CSF) and blood, and the role of neuroimmune factors in the pathogenesis of myelopathies. Along with others neurologists and health care providers in the Johns Hopkins Transverse Myelitis Center, Dr. Pardo focuses on a comprehensive approach in the diagnosis and management of myelopathies, myelitis, neuroimmunological and neuroinfectious disorders. Dr. Pardo is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Acute Flaccid Myelitis (AFM), Neurosarcoidosis, Transverse Myelitis, Zika Virus Disease, and Gastrostomy.

Dr. Ricardo Roda earned a combined MD/PhD degree from University of Rochester and completed an adult neurology residency, followed by a clinical neuromuscular fellowship at Johns Hopkins University School of Medicine. During residency, Dr. Roda developed a special interest in both auto-immune disorders and genetic disorders. Following residency, he spent three years in neurogenetics branch of National Institute of Neurological Disorders and Stroke (NINDS) working with Dr. Craig Blackstone, focusing on the use of the newer DNA sequencing techniques in genetic diagnosis, and in establishing genotype/phenotype correlations neuromuscular disorders. His current clinical interests include developing testing strategies for undiagnosed genetic disorders and myasthenia gravis. Dr. Roda is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Spastic Paraplegia Type 7, Hereditary Spastic Paraparesis, Myasthenia Gravis, and Spastic Paraplegia Type 2.

Dr. Moukheiber trained in neurology at Tufts Medical Center and completed his fellowship in movement disorders at Johns Hopkins. His primary interests include using telehealth/teleneurology to help bridge the gap between tertiary care available in well-funded facilities and the dearth of it in significantly underserved and remote areas; especially pertaining to movement disorders in general and ataxia in particular. He has worked with a number of non-government organizations and founded his own entity that provides home health care in the form of advanced nursing, physical therapy and occupational therapy to underserved communities in third world countries, with particular emphasis on neurodegenerative diseases. Dr. Moukheiber is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Stiff Person Syndrome, Movement Disorders, Parkinson's Disease, and Drug Induced Dyskinesia.

Dr. Leung obtained her undergraduate degree in biochemical sciences from Harvard University. While attending medical school at Duke University, she completed a year-long research fellowship studying genetic markers of late-onset Alzheimer’s disease at the National Institute on Aging as part of the NIH Clinical Research Training Program. She completed her neurology residency and clinical neurophysiology fellowship at Stanford University Medical Center, and is currently a Ph.D. candidate in the graduate training program in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Leung joined the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute as a translational research fellow in 2010 and was appointed to the faculty in 2014. Her clinic specializes in electromyography and the diagnosis and treatment of hereditary muscle diseases. Dr. Leung’s research focuses on the development of imaging biomarkers and outcome measures for muscle diseases. She is the principal investigator for a longitudinal cohort study of whole-body MRI in facioscapulohumeral muscular dystrophy. Dr. Leung is also a site principal investigator for the Ionis-DMPKRx trial, a phase Ib/IIa clinical trial of a novel RNA-based therapy for myotonic muscular dystrophy. Dr. Leung is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Facioscapulohumeral Muscular Dystrophy (FSHD), Dysferlinopathy, Limb-Girdle Muscular Dystrophy Type 2I, and Limb-Girdle Muscular Dystrophy.

Dr. Bipasha Mukherjee-Clavin is an Assistant Professor of Neurology in the Johns Hopkins University School of Medicine. She cares for patients with neuromuscular disorders, with a special focus on patients with peripheral neuropathy, immune-mediated neuropathy, and inherited neuropathy (also known as Charcot-Marie-Tooth disease). She sees patients in the Johns Hopkins Peripheral Nerve and multidisciplinary Charcot-Marie-Tooth clinics, and performs electromyography in the Johns Hopkins EMG lab. As a stem cell biology-trained scientist, Dr. Mukherjee-Clavin's research is focused on the use of patient-derived induced pluripotent stem cells to model genetic Schwann cell and peripheral nerve disorders to undercover novel pathways and potential treatments. During her PhD she published one of the first studies of CMT1A using patient derived stem cells (Comparison of three congruent patient-specific cells types for the modelling of a human genetic Schwann-cell disorder. Nature Biomedical Engineering. volume 3, pages 571–582 (2019)). In 2022, she was awarded the Passano award, given to a promising early career physician-scientist in the Johns Hopkins University School of Medicine. Dr. Mukherjee-Clavin completed her undergraduate studies at the University of California, Berkeley. She then completed her MD/PhD degrees, Neurology residency, and clinical Neuromuscular fellowship in the Johns Hopkins University School of Medicine. She joined the Johns Hopkins Neurology faculty in 2022. Dr. Mukherjee is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Charcot-Marie-Tooth Disease, Miller-Fisher Syndrome, Guillain-Barre Syndrome, and Chronic Polyradiculoneuritis.

Lindsay Zilliox is a Neurologist in Baltimore, Maryland. Dr. Zilliox is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Peripheral Neuropathy, Orthostatic Hypotension, Diabetic Neuropathy, Familial Dysautonomia, and Gastrostomy.

Evgeny Tsimerinov is a Neurologist in Columbia, Maryland. Dr. Tsimerinov is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Cervical Myelopathy, Dysembryoplastic Neuroepithelial Tumors (DNET), Invertebral Disc Disease, and Brain Stem Cancer.

Bruce Rabin is a Neurologist in Lutherville, Maryland. Dr. Rabin is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Myasthenia Gravis, Cerebellar Degeneration, Relapsing Multiple Sclerosis (RMS), and Multiple Sclerosis (MS).

Diana Escolar is a Neuromusculoskeletal Medicine provider in Baltimore, Maryland. Dr. Escolar is rated as an Experienced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. Her top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Primary Lateral Sclerosis, and Spinal Muscular Atrophy Type 2.